Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label dose-ranging study of seladelpar in primary biliary cholangitis
2016-002996-91Phase 2Completed
- Sponsor
- CymaBay Therapeutics
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of seladelpar in primary biliary cholangitis (PBC) (4 arms), sponsored by CymaBay Therapeutics. Primary endpoint: Serum alkaline phosphatase. Started Nov 2016; status: completed.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2016-002996-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002996-91.